Log in to save to my catalogue

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811291407

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Migalastat stabilizes mutant α-galactosidase in Fabry's disease, reducing globotriaosylceramide deposition. In this study, the percentage of patients with a decrease of 50% or more in kidney interstitial capillary deposition at 6 months was similar in the migalastat and placebo groups.
Fabry’s disease is a rare, progressive, and devastating X-li...

Alternative Titles

Full title

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1811291407

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1811291407

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1510198

How to access this item